8-K: TuHURA Biosciences to Acquire Kineta, Bolstering Pipeline with Novel Checkpoint Inhibitor

TuHURA Biosciences has entered into a definitive agreement to acquire Kineta, gaining access to a Phase 2 novel checkpoint inhibitor and expanding its immuno-oncology pipeline.

Summary

• TuHURA Biosciences has agreed to acquire Kineta, a clinical-stage biotech company, in a merger transaction.
• The acquisition includes Kinetas novel KVA12123 antibody, a VISTA-inhibiting immunotherapy.
• The merger consideration involves a combination of cash and TuHURA common stock.
• The base cash amount is $9,005,000, adjusted for Kinetas working capital deficit and any working capital loans from TuHURA.
• Up to approximately 3,476,568 shares of TuHURA common stock will be issued, with a portion held back for potential liabilities.
• Kineta stockholders may also receive a pro rata share of proceeds from any pre-closing asset sales.
• TuHURA will provide up to $900,000 in funding for KVA12123 clinical trials and may provide up to $2,000,000 in working capital loans to Kineta.
• The transaction is expected to close in the first quarter of 2025, pending approvals and other conditions.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook on the acquisition, highlighting the strategic fit and potential of KVA12123. The language is optimistic, focusing on synergies and future development plans. However, the document also acknowledges the risks and uncertainties associated with the transaction, which tempers the overall sentiment.

Positives

• The acquisition adds a Phase 2 novel checkpoint inhibitor, KVA12123, to TuHURAs pipeline.
• KVA12123 has shown strong monotherapy tumor growth inhibition in preclinical models without evidence of cytokine release syndrome in clinical trials.
• KVA12123 has a differentiated mechanism of action that is complementary with T cell focused therapies.
• The acquisition is expected to create synergies with TuHURAs existing technologies.
• The transaction is expected to maximize shareholder value for Kineta.

Negatives

• The cash component of the merger consideration is subject to adjustments based on Kinetas working capital deficit and any working capital loans from TuHURA.
• A portion of the TuHURA common stock issued will be held back for six months to satisfy potential liabilities.
• The transaction is subject to various closing conditions, including stockholder approvals and the effectiveness of a registration statement.

Risks

• The transaction may not close on the anticipated timeline or at all.
• There are risks related to Kinetas cash level and ability to continue as a going concern.
• The price of TuHURA common stock could change before the completion of the transaction.
• There are risks related to the amount of Kinetas estimated net working capital at closing.
• There are uncertainties as to access to available financing to complete the transaction.
• The transaction may not qualify as a tax-free reorganization.
• There are risks that the transaction could disrupt current plans and operations of Kineta or TuHURA.
• There is a risk of no amounts being payable under the Disposed Asset Payment Right.
• There is a potential dilution of TuHURA and Kineta stockholders ownership percentage of TuHURA after the transaction.

Future Outlook

The Proposed Transaction is expected to close in the first quarter of 2025, pending approvals and other conditions. TuHURA plans to initiate a Phase 2a/b trial with KVA12123 in mutated NPM1 AML in 2025.

Management Comments

• James Bianco, M.D., President and Chief Executive Officer of TuHURA, believes the PK/PD profile of KVA12123 positions it as a potential best-in-class VISTA-inhibiting antibody.
• Craig W. Philips, President of Kineta, believes the acquisition by TuHURA maximizes shareholder value and provides an exciting development path forward for KVA12123.

Industry Context

This acquisition reflects a trend in the biopharmaceutical industry where companies are seeking to expand their pipelines through strategic mergers and acquisitions, particularly in the immuno-oncology space. The focus on VISTA as a target highlights the growing interest in novel checkpoint inhibitors to overcome resistance to existing immunotherapies.

Comparison to Industry Standards

• KVA12123 is being developed as a monoclonal antibody infusion drug dosed every two-week cycles, which is a common approach for checkpoint inhibitors.
• The focus on VISTA as a target is notable as other companies like Jounce Therapeutics and Immutep are also developing VISTA-targeting therapies, but KVA12123 is differentiated by its unique epitope binding and optimized IgG1 Fc region.
• The combination of KVA12123 with pembrolizumab is similar to other checkpoint inhibitor combination strategies being explored in the industry.
• The focus on mNPM1 AML is a specific niche within the broader AML market, where there is a high unmet need for effective therapies.

Stakeholder Impact

• Kineta stockholders will receive a combination of cash and TuHURA common stock.
• TuHURA stockholders will see a potential expansion of the company's pipeline and future growth opportunities.
• Employees of both companies may experience changes due to the integration process.
• Patients may benefit from the development of new cancer therapies.

Next Steps

• Kineta stockholders will vote on the approval of the merger agreement.
• TuHURAs stockholders will vote on the approval of an increase in the number of authorized shares of TuHURA common stock.
• TuHURA will file a registration statement on Form S-4 with the SEC.
• TuHURA will continue to fund clinical trial expenses for KVA12123.
• Kineta will continue to pursue partnership opportunities for its non-KVA12123-related products and technologies.
• TuHURA plans to initiate a Phase 2a/b trial with KVA12123 in mutated NPM1 AML in 2025.

Key Dates

Keywords

merger, acquisition, immuno-oncology, checkpoint inhibitor, VISTA, KVA12123, clinical trial, biotechnology, cancer, TuHURA Biosciences, Kineta